Ironwood Pharmaceuticals, Inc.
IRWD
$3.25
-$0.12-3.56%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -47.31% | 33.26% | -9.70% | -45.05% | -22.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -47.31% | 33.26% | -9.70% | -45.05% | -22.98% |
| Cost of Revenue | -13.89% | -24.67% | -23.08% | 6.26% | -35.52% |
| Gross Profit | -60.33% | 61.24% | -3.35% | -72.05% | -16.66% |
| SG&A Expenses | -42.56% | -39.33% | -54.56% | -35.49% | -28.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.22% | -32.70% | -40.36% | -18.49% | -31.69% |
| Operating Income | -79.24% | 202.84% | 66.66% | -192.07% | 1.13% |
| Income Before Tax | -98.10% | 291.62% | 100.37% | -831.59% | -20.97% |
| Income Tax Expenses | -87.44% | 103.60% | -27.93% | -87.79% | -32.29% |
| Earnings from Continuing Operations | -200.89% | 999.29% | 2,844.07% | -798.27% | 229.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -200.89% | 999.29% | 2,844.07% | -798.27% | 307.54% |
| EBIT | -79.24% | 202.84% | 66.66% | -192.07% | 1.13% |
| EBITDA | -78.12% | 198.78% | 65.29% | -184.13% | 1.03% |
| EPS Basic | -199.29% | 983.77% | 2,801.85% | -779.55% | 301.43% |
| Normalized Basic EPS | -99.15% | 297.94% | 76.43% | -421.50% | -6.18% |
| EPS Diluted | -270.92% | 1,047.00% | 1,474.00% | -674.00% | 274.07% |
| Normalized Diluted EPS | -99.15% | 264.16% | 61.36% | -421.50% | -6.48% |
| Average Basic Shares Outstanding | 1.59% | 1.57% | 1.70% | 2.08% | 2.49% |
| Average Diluted Shares Outstanding | 1.26% | 10.94% | 11.21% | 2.08% | 2.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |